OncoResponse to Present Phase 1 Results of Clinical Study of OR502, anti-LILRB2 Antibody, as a Late-Breaker Poster Presentation at SITC 2024

HOUSTON, Nov. 4, 2024 /PRNewswire/ — OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of Elite Cancer Responders, today announced that it will present Phase 1 results for the clinical study of OR502, a novel, humanized anti-leukocyte immunoglobulin like receptor B2 (LILRB2) antibody that rescues innate and adaptive immune responses from LILRB2 mediated immune suppression. The Phase 1 study results will be presented as a late-breaker poster presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024), taking place in Houston, Texas, November 8-10, 2024.

Details are as follows:

Title (Late-Breaking Abstract): Phase 1 results of OR502, an antibody against leukocyte immunoglobulin-like receptor B2 (LILRB2), in subjects with advanced cancers

Abstract Number: 1464
Details: Saturday, November 9, George R. Brown Convention Center

Title: Adaptive design elements in a Ph 1-2 study of OR502, a novel antibody against leukocyte immunoglobulin-like receptor B2 (LILRB2), in response to evolving Ph 1 data and changing regulatory environment

Abstract Number: 680
Details: Saturday, November 9, George R. Brown Convention Center

OncoResponse poster presentations from SITC are available on the Publications page of the Company website following their respective sessions.

About OncoResponse

OncoResponse is a clinical-stage, immuno-oncology biotech company developing cancer immunotherapies using clues from the immune systems of Elite Cancer Responders. In a broad strategic alliance with MD Anderson Cancer Center, OncoResponse deploys a proprietary B-cell discovery platform to identify and develop novel antibodies targeting immune cells in the tumor microenvironment. The company’s lead clinical candidate, OR502 is a best-in-class anti-LILRB2 antibody that rescues innate and adaptive immune responses from LILRB2-mediated immune suppression and entered clinical study in 2023. OR502 clinical studies are being conducted with support from the Cancer Prevention Research Institute of Texas (CPRIT) DP230076. For more information please visit www.oncoresponse.com and follow us on LinkedIn and X.

Media Contact:
Julie Rathbun
Rathbun Communications
+1.206.769.9219
julie@rathbuncomm.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/oncoresponse-to-present-phase-1-results-of-clinical-study-of-or502-anti-lilrb2-antibody-as-a-late-breaker-poster-presentation-at-sitc-2024-302295055.html

SOURCE OncoResponse

Staff

Recent Posts

poLight ASA receives purchase order for TWedge® wobulator technical samples from a top tier consumer OEM customer

TØNSBERG, Norway, Nov. 21, 2024 /PRNewswire/ -- poLight ASA (OSE: PLT) today announced that the…

3 hours ago

Waud Capital Partners Releases First Annual Responsible Investing Report

CHICAGO, Nov. 21, 2024 /PRNewswire/ -- Waud Capital Partners ("Waud Capital"), a growth-oriented middle-market private equity…

3 hours ago

Rightway Partners with Curai Health to Expand Access to High-Quality, Affordable Virtual Care

NEW YORK, Nov. 21, 2024 /PRNewswire/ -- Today, Rightway, a company transforming care navigation and pharmacy…

3 hours ago

Aires Tech Showcases Advanced Technology at UFC Performance Institute with “Next Frontier of UFC Training and Performance” Symposium

Symposium gathered top fighters, neuroscientists, and media together in New York City on eve of UFC…

3 hours ago

Space-Grown Brain Organoids Help Advance New Neurological Treatment

Startup Leverages ISS National Lab to Test Viral Vector That Delivers Gene Therapy KENNEDY SPACE…

3 hours ago

Mindray Strengthens its Office-based Ultrasound Machine Portfolio Debuting the Consona-Series

 Mindray continues to push the boundaries of private practice ultrasound machine innovation MAHWAH, N.J., Nov.…

3 hours ago